Home Breast Cancer Biomarkers Breast Cancer Gene Panel Test: BRCA, PALB2, CHEK2, ATM, and Hereditary Risk

Breast Cancer Gene Panel Test: BRCA, PALB2, CHEK2, ATM, and Hereditary Risk

By
Vita Library
-
30
Breast cancer gene panel testing explained: BRCA1/2, PALB2, CHEK2, ATM, positive and VUS results, hereditary risk, screening, and family testing.

A hereditary breast cancer gene panel tests several cancer-predisposition genes at the same time instead of looking only at BRCA1 and BRCA2. Common panels include BRCA1, BRCA2, PALB2, CHEK2, and ATM and may also include TP53, PTEN, CDH1, STK11, and other genes chosen for the person’s history. The advantage is breadth: one blood or saliva test can find an inherited cause that would be missed by BRCA-only testing. The tradeoff is complexity. Different genes carry very different levels of breast cancer risk, and a pathogenic variant in CHEK2 or ATM should not automatically be managed as though it were a BRCA1 variant. Panels also increase the chance of a variant of uncertain significance (VUS), which should not be used as a reason for preventive surgery or treatment. Good interpretation therefore depends on the exact gene, exact variant classification, family history, age, and current clinical guidelines.

  • Multigene panels usually use blood or saliva and can evaluate BRCA1/2 plus other inherited breast cancer genes in one test.
  • PALB2 is generally considered a higher-risk breast cancer gene; CHEK2 and ATM usually confer more moderate, variant-dependent risk.
  • A pathogenic or likely pathogenic variant can change screening and family testing, but a VUS should not be treated as a disease-causing result.
  • Current breast cancer guidance supports broader germline testing when results can affect treatment, personal risk, or family risk.
  • Risk-reducing surgery is not automatically recommended for every panel-positive result; management is gene- and risk-specific.

Table of Contents

What a Hereditary Breast Cancer Gene Panel Tests

A hereditary panel looks for germline variants—changes present from birth in essentially every cell. The sample is usually blood or saliva. The laboratory sequences multiple genes and often assesses larger deletions or duplications as well. The exact gene list varies, so “negative panel” has meaning only when the report shows which genes and variant types were actually evaluated.

The genes are connected by cancer biology, but they are not clinically interchangeable. BRCA1, BRCA2, and PALB2 participate in homologous-recombination DNA repair. ATM and CHEK2 are also involved in DNA-damage signaling and repair, but their average penetrance is lower and risk can vary by the specific variant and family context. Other panel genes may act through different pathways and be associated with distinct cancer syndromes.

A panel can be more efficient than sequential testing when the history could fit several syndromes. For example, breast cancer at a young age plus pancreatic cancer in the family could be explained by BRCA2 or PALB2, while very early breast cancer plus sarcoma or brain tumors could raise concern for TP53. Diffuse gastric cancer and lobular breast cancer can point toward CDH1. The history helps determine whether a broad panel adds value and whether the laboratory’s gene list is appropriate.

A panel is not a tumor profiling test. Tumor sequencing looks for acquired changes that may guide cancer therapy. Some variants found in the tumor are also germline, so a clinically important tumor finding can trigger confirmatory hereditary testing. A separate BRCA1/2 germline test may be sufficient in some cases, but a multigene approach reduces the chance of stopping after BRCA when another established hereditary gene is responsible.

BRCA1, BRCA2, and PALB2: Higher-Risk Findings

BRCA1 and BRCA2 remain the best-known hereditary breast cancer genes. Pathogenic variants can confer a high lifetime risk of female breast cancer and increase the risk of a second primary breast cancer. They are also associated with ovarian, pancreatic, prostate, and other cancers to varying degrees. In people with breast cancer, BRCA status can influence PARP-inhibitor eligibility in defined settings as well as long-term risk management.

PALB2 is a major BRCA2 partner in homologous-recombination repair. It was once treated as a less-established panel finding, but large studies and professional guidance now support clinically important breast cancer risk. A 2024 meta-analysis estimated breast cancer risk for PALB2 pathogenic-variant carriers at about 12.8% by age 50 and 48.5% by age 80, with wide confidence intervals and substantial influence from family history and study design. ACMG guidance recommends BRCA1/2-equivalent breast surveillance for PALB2 carriers and allows consideration of risk-reducing mastectomy using personalized risk rather than the gene label alone.

The PALB2 result also has implications for relatives and may be relevant to pancreatic and ovarian cancer risk. The exact recommendations depend on family history, age, sex, country, and evolving guidelines.

Even among “high-risk” genes, one number does not fit every person. Risk estimates are population averages. A carrier with many relatives affected at young ages may have a different modeled risk from a carrier with no close family history, and prior removal of breast or ovarian tissue changes future absolute risk. Counseling should translate the gene result into a personal risk estimate whenever possible.

CHEK2 and ATM: Moderate-Risk Results Need Different Interpretation

CHEK2 and ATM illustrate why all positive panel findings should not be managed like BRCA1. Both are generally considered moderate-penetrance breast cancer genes, and risk can be modified by the exact variant, family history, polygenic background, and other factors.

ACMG’s 2023 CHEK2 practice resource emphasizes personalized risk assessment. Truncating CHEK2 variants are generally associated with a moderate increase in female breast cancer risk, but some missense variants carry lower or uncertain risk. Enhanced breast surveillance may be appropriate when the calculated risk crosses guideline thresholds. Risk-reducing mastectomy is not a default recommendation solely because “CHEK2 positive” appears on a report; it is considered in the context of individualized risk and patient preference. A dedicated CHEK2 variant interpretation can help distinguish gene-level reputation from variant-level evidence.

ATM works similarly in principle. The 2025 ACMG practice resource describes ATM as a moderate-risk gene and recommends enhanced breast surveillance according to personalized risk and local guidance. In general, risk-reducing mastectomy is not routinely recommended based on ATM status alone. Some specific ATM variants may confer higher risk than the average ATM pathogenic variant, which again makes exact variant interpretation important.

An ATM result also should not automatically lead to avoidance of standard breast radiotherapy. Current ACMG guidance states that radiation-therapy decisions for heterozygous ATM pathogenic-variant carriers should not be changed simply because of the genetic result. That is an important example of why older assumptions about a gene can persist after expert guidance has become more nuanced.

Moderate risk does not mean trivial risk. It means management depends more heavily on the complete risk model rather than on a single gene-triggered action.

Who Should Have Multigene Panel Testing

The 2024 ASCO–Society of Surgical Oncology guideline broadened germline testing in breast cancer. BRCA1/2 testing should be offered to all newly diagnosed patients age 65 or younger and selected older patients. Testing for genes beyond BRCA1/2 is recommended when family history supports it and when results would affect management. That is where panel selection becomes important.

A panel is particularly useful when the pattern is not specific to one gene: multiple relatives with breast cancer, breast plus pancreatic cancer, male breast cancer, ovarian cancer, early-onset disease, multiple primary cancers, or a family structure too small to reveal a classic syndrome. Prior negative BRCA1/2 testing from years ago can also be a reason to revisit testing if the original assay was narrow or if additional genes are now clinically actionable.

Testing an affected relative first remains the most informative strategy when possible. If a pathogenic variant is found, unaffected relatives can then have targeted testing. If an unaffected person has a broad panel with no affected relative available, a negative result may leave substantial uncertainty because the family’s underlying cause was never established.

Panel size should be intentional. Very large panels may include genes with weak or emerging breast cancer associations, increasing uncertain findings without necessarily improving care. A genetics professional can choose a panel that covers established, actionable genes relevant to the family instead of simply ordering the largest available test.

Testing can also be time-sensitive in a newly diagnosed patient if a germline result could influence systemic therapy or surgery. In that setting, rapid testing may be appropriate, but speed should not bypass informed consent or careful interpretation.

How to Read Positive, Negative, and VUS Panel Results

A pathogenic or likely pathogenic result means there is sufficient evidence that the variant disrupts gene function in a way associated with disease. The next step is gene-specific risk interpretation: What cancers are established for this gene? What is the penetrance? Does the exact variant change the risk estimate? Which surveillance or prevention options are supported?

A negative panel means no reportable pathogenic variant was found in the genes and variant types tested. It can be strongly reassuring when the test specifically rules out a known family variant. It is less definitive when no cause has been identified in an affected relative. The family history may still justify enhanced breast screening even after a negative panel.

A VUS is an uncertain result, not a “partial positive.” Multigene panels produce more VUS results than single-gene tests simply because more DNA is examined. Most VUS findings are eventually downgraded to benign or likely benign, although the outcome for any individual variant cannot be predicted. Professional guidance consistently advises that medical management should not be based on a VUS.

The gene name alone is not enough. For example, a low-risk CHEK2 missense variant should not be interpreted like a classic truncating CHEK2 pathogenic variant, and neither should be interpreted as a BRCA1 pathogenic variant. Reports should be read to the full variant level, including classification and any laboratory comments about penetrance.

Reclassification is possible. Patients should know which laboratory performed the test and how updates are communicated. If a family history changes—for example, a relative develops pancreatic or ovarian cancer—the genetics team may also reconsider whether the original panel was sufficient.

How Panel Results Change Screening, Prevention, and Treatment

A pathogenic panel result can change breast screening by supporting earlier or more intensive imaging, often including MRI when risk is high enough. The exact starting age and modality depend on the gene and guideline. For high-risk genes such as BRCA1/2 and PALB2, surveillance is generally more intensive than for average-risk populations. For CHEK2 and ATM, the plan is more often tied to a modeled lifetime risk and family history.

Risk-reducing mastectomy deserves individualized discussion rather than a reflex response. It is commonly considered for BRCA1/2 and may be considered for PALB2 when personalized risk is high. For CHEK2 and ATM, expert guidance generally does not recommend prophylactic mastectomy solely because of the gene result, although a strong family history may shift the balance.

Other organs matter. BRCA1/2 can alter ovarian-risk management; BRCA2, ATM, and some other genes can affect pancreatic or prostate surveillance discussions; TP53 has a very different multi-organ surveillance framework. A “breast cancer panel” result can therefore create non-breast recommendations that should be handled with syndrome-specific expertise.

Treatment implications are also gene-specific. Germline BRCA1/2 has established relevance to PARP inhibitors in defined breast cancer settings. Evidence for using the same strategy solely because of other homologous-recombination genes is not automatically equivalent. Clinicians should use the current drug label and disease-specific guideline rather than generalizing from pathway biology.

Finally, a hereditary gene result does not replace tumor markers. ER, PR, HER2, and other tumor biomarkers still determine subtype and major treatment choices. The tumor biomarker profile and the germline panel answer different questions and should be interpreted side by side.

Family Testing and Practical Next Steps

Each autosomal-dominant pathogenic variant found on a hereditary cancer panel can have implications for first-degree relatives, who usually have a 50% chance of carrying the same variant. Once the familial variant is known, targeted cascade testing is usually more efficient and more interpretable than ordering a fresh broad panel for every relative.

Relatives should receive the exact report or a genetics letter that names the gene and variant. “We have a cancer gene in the family” is not specific enough for clinical testing. Adult relatives can then decide whether and when to test based on whether the result would change screening, prevention, or reproductive planning.

The result may come from either side of the family. A father can transmit BRCA1, BRCA2, PALB2, CHEK2, ATM, or other autosomal-dominant variants to daughters or sons. Family histories that focus only on women can therefore miss important clues such as prostate, pancreatic, or male breast cancer.

After testing, ask for a written management plan that separates immediate actions from future ones. A newly diagnosed patient may need an answer about treatment or surgery first. Later visits can address screening of the opposite breast, ovarian or pancreatic risk when relevant, family testing, and whether recommendations should be revisited as the patient ages.

For a VUS, the practical plan is different: do not test healthy relatives for routine medical decisions, do not use the VUS to justify surgery, and keep contact information current for reclassification. For a negative result in a strongly affected family, continue risk assessment based on the pedigree and ask whether future updated testing could be useful.

The goal of a panel is not to produce the longest list of genes. It is to convert an inherited finding into precise, evidence-based actions for the person tested and for relatives who choose to know their status.

Choosing the right panel size

A larger panel is not automatically a better panel. The best test includes genes with a credible connection to the person’s cancer history and with results that can be interpreted or acted on. Very broad panels can identify pathogenic variants outside the original question, but they also increase the chance of uncertain findings in genes whose breast-cancer risk is small, poorly quantified, or dependent on the exact variant. That can make counseling harder without improving care.

Before testing, it is useful to ask what would change if a result were positive. A BRCA1, BRCA2, PALB2, TP53, PTEN, or CDH1 finding may trigger very different screening, surgery, or family recommendations. CHEK2 and ATM generally require individualized risk modeling rather than automatic BRCA-style management. Some genes on commercial panels may have strong evidence for another cancer but weak evidence for breast cancer. The laboratory’s gene list should therefore be matched to the clinical question rather than accepted as a generic package.

After testing, interpretation should stay variant-specific. A pathogenic truncating CHEK2 variant, for example, is not necessarily equivalent in risk to every CHEK2 missense variant. ATM also contains variants with different evidence and risk estimates. Management guidelines increasingly emphasize the exact molecular finding, family history, and modeled absolute risk instead of relying on the gene name alone.

This approach reduces two opposite errors: underreacting to a genuinely high-risk finding and overreacting to a moderate or uncertain one. The purpose of panel testing is to make risk assessment more precise. That precision is lost when every “positive gene” is treated as if it carries the same lifetime risk or requires the same surgery.

References

Disclaimer

This article is for general education about hereditary breast cancer gene panels. The meaning of a result depends on the exact gene, variant, personal history, and family history; decisions about screening, surgery, or treatment should be made with genetics and cancer-care professionals using current guidance.

RELATED ARTICLESMORE FROM AUTHOR